ArticleCancer biomarkers : section A of Disease markers2021
Association between baseline Controlling Nutritional Status score and clinical outcomes of patients with multiple myeloma.
Article in Cancer biomarkers : section A of Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis.BMC cancer · 2022Pooled it
- Prognostic Effect of Sarcopenia and Nutritional Factors on Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Exploratory Study.Journal of cachexia, sarcopenia and muscle · 2026Article
- Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Significance of Pre-Transplant Controlling Nutritional Status Score.Life (Basel, Switzerland) · 2025Article
- Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies.Frontiers in nutrition · 2025Review
- Effectiveness of CONUT and NRI as nutritional risk screening tools in peritoneal dialysis: a multicenter study.Frontiers in nutrition · 2025Article
- Prognostic value of the Controlling Nutritional Status score in patients with newly diagnosed multiple myeloma.American journal of translational research · 2024Article
- The controlling nutritional status score as a predictor of survival in hematological malignancies: a systematic review and meta-analysis.Frontiers in nutrition · 2024Review
- Article
- Controlling nutritional status score is associated with renal progression, cardiovascular events, and all-cause mortality in biopsy-proved diabetic kidney disease.Frontiers in physiology · 2023Article
- Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma.Journal of inflammation research · 2023Article
- Prognostic value of the controlling nutritional status score in patients with myelodysplastic syndromes.Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Controlling Nutritional Status (CONUT) score, a novel immuno-nutritional index, was reported as a predictor of overall survival (OS) in some tumors.
objectiveWe aimed to investigate the association between baseline CONUT Score and clinical outcomes in patients with multiple myeloma (MM).
methodsWe performed a retrospective analysis of 245 patients with MM. The CONUT score was determined prior to therapy.
resultsAmong the entire cohort, the complete remission rate was markedly higher in the low-CONUT (⩽ 3) group compared to the mid-CONUT (4-9) group or high-CONUT (> 9) group (44.1% vs 25.8%, P= 0.039; 44.1% vs 12.5%, P= 0.002). Patients with CONUT score > 9 had significant poor prognosis, and CONUT score ⩽ 3 group showed better survival outcome than other groups in OS (P< 0.001). Besides, we stratified the patients by combining International Staging System (ISS) stage and CONUT score in a model, and found that CONUT score could improve the prognostic impact of ISS stages on OS. In multivariate analysis, older age (⩾ 70 years) and a high CONUT score (⩾ 4) were independent prognostic risk factors for OS.
conclusionsThe CONUT score was a predictor of OS in MM patients especially in cases with both low ISS staging and CONUT score. The baseline CONUT score may be an early and practical indicator of the efficacy of anti-myeloma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.